All data are based on the daily closing price as of November 13, 2026
d
Dong-A Socio Holdings
000640.KO
66.00 USD
-3.35
-4.83%
Overview
Last close
66.00 usd
Market cap
444.16M usd
52 week high
89.53 usd
52 week low
48.97 usd
Target price
108.61 usd
Valuation
P/E
7.2943
Forward P/E
13.6054
Price/Sales
0.3911
Price/Book Value
0.4977
Enterprise Value
785.44M usd
EV/Revenue
0.6908
EV/EBITDA
9.6976
Key financials
Revenue TTM
1.14B usd
Gross Profit TTM
361.82M usd
EBITDA TTM
154.16M usd
Earnings per Share
9.49 usd
Dividend
1.27 usd
Total assets
1.43B usd
Net debt
249.41M usd
About
Dong-A Pharmaceutical Co.,Ltd., together with its subsidiaries, engages in the pharmaceutical business in South Korea. It operates through a Holding Company; Over-the-Counter Drugs and Quai-Drugs; Biosimilars and Consignment Medicines; Logistics; Packaging Solutions; and Others segments. The company develops DA-8010 in Phase 3 clinical trial to treat overactive bladder; DMB-3115, a biosimilar of Stelara in Phase 3 clinical trial; DA-1241 in Phase 2 clinical trial for the treatment of non-alcoholic steatohepatitis; DA-1726 in Phase 1 clinical trial to treat obesity; and STP0404 for the treatment of AIDS. It also provides medical devices and equipment; healthcare solutions to customers in Bacchus, over-the-counter, consumer healthcare, and cosmetics; health functional food; contract development and manufacturing organization for biosimilar and pharmaceutical products, and oligonucleotide therapeutics; functional sports drinks under the POCARI SWEAT brand; logistics and fulfillment services; glass bottles, PET bottles, aluminum and plastic caps, and paper packaging boxes; mineral and carbonated water, and mixed drinks; and IT and construction services. In addition, the company is involved in engineering; cargo, courier, and automobile transport arrangements; transportation warehousing and leasing; real estate development; agricultural product distribution; management consulting; business management; and architectural, electrical work, fire protection, and housing contracting services. The company was formerly known as Dong-A Socio Holdings Co., Ltd. and changed its name to Dong-A Pharmaceutical Co.,Ltd. in October 2026. Dong-A Pharmaceutical Co.,Ltd. was founded in 1932 and is headquartered in Seoul, South Korea.